Orexo’s best Q2 yet – Updated 16 July
Net sales grew by 25.5% y/y to SEK 200m in Q2. The main growth drivers were Zubsolv US sales, which grew 28% in SEK, ie 30% y/y in local currency, and a milestone payment of SEK 31m by Mundipharma due to the European launch of Zubsolv in June 2018. The US market for buprenorphine-naloxone (BNX) maintained momentum and Orexo’s Zubsolv was the only branded competitor to gain market share compared to Q1.
|Commissioned research: Combatting the US opioid epidemic, 27 June 2018|
|Orexo is a fully integrated, speciality pharmaceuticals company based in Uppsala, Sweden, and with commercial operations in the US. Its 2017 revenue stemmed mostly from opioid addiction (76%) and breakthrough cancer pain (18%) drugs, based on its proprietary formulation technology platform. Orexo had an EBITDA margin of 12% in 2017, which we estimate will increase to 17% by 2019.
Marketing material commissioned by Orexo.
To learn more on Commissioned Research, please click here
The information provided within this website is intended for background information only. The views and other information provided herein are the current views of Nordea Markets as of the date of publication and are subject to change without notice. The information provided within this website is not an exhaustive description of the described product or the risks related to it, and it should not be relied on as such, nor is it a substitute for the judgement of the recipient.
The information provided within this website is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information provided within this website has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision. It is important to note that past performance is not indicative of future results.
Nordea Markets is not and does not purport to be an adviser as to legal, taxation, accounting or regulatory matters in any jurisdiction.
The information provided within this website may not be reproduced, distributed or published for any purpose without the prior written consent from Nordea Markets.